HLB BIOSTEP CO.,LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,560 KRW | +0.39% |
|
-18.47% | -17.15% |
| May. 20 | HLB bioStep Co.,Ltd. announces an Equity Buyback for KRW 3,000 million worth of its shares. | CI |
| May. 20 | HLB bioStep Co.,Ltd. authorizes a Buyback Plan. | CI |
| Sales 2022 | 86.28B 62.98M | Sales 2023 | 52.81B 38.55M | Capitalization | 243B 177M |
|---|---|---|---|---|---|
| Net income 2022 | -3B -2.19M | Net income 2023 | -164M -120K | EV / Sales 2022 | 3.74 x |
| Net cash position 2022 | 5.42B 3.96M | Net cash position 2023 | 9.74B 7.11M | EV / Sales 2023 | 4.41 x |
| P/E ratio 2022 |
-108
x | P/E ratio 2023 |
-1,445
x | Employees | 161 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 70.52% |
More Fundamentals
* Assessed data
More news
| 1 day | -0.20% | ||
| 1 week | -18.79% | ||
| Current month | -31.64% | ||
| 1 month | -34.02% | ||
| 3 months | -29.85% | ||
| 6 months | -5.20% | ||
| Current year | -17.48% |
1 week
2 230.00
2 820.00
1 month
2 200.003 980.00
Current year
2 200.004 705.00
1 year
2 200.004 705.00
3 years
2 200.0043 950.00
5 years
1 122.2243 950.00
10 years
1 122.2243 950.00
| Managers | Title | Age | Since |
|---|---|---|---|
Do-Hyeong Kim
CEO | Chief Executive Officer | 44 | - |
Jung-Hwan Moon
CEO | Chief Executive Officer | 61 | - |
Do-Guk Son
DFI | Director of Finance/CFO | 49 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Yang-Gon Jin
BRD | Director/Board Member | 58 | - |
Chang-Yoon Lim
BRD | Director/Board Member | 58 | - |
Jung-Hwan Moon
CEO | Chief Executive Officer | 61 | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-23 | 2,560 | +0.39% | 1 465 135 |
| 24-05-23 | 2,550 | -0.20% | 4,903,019 |
| 24-05-22 | 2,555 | -2.11% | 3,505,518 |
| 24-05-21 | 2,610 | +13.97% | 22,051,040 |
| 24-05-20 | 2,290 | +4.09% | 8,879,839 |
End-of-day quote Korea S.E., May 22, 2024
More quotes
HLB bioStep Co Ltd, formerly KNOTUS Co Ltd, is a Korea-based company mainly engaged in non-clinical trial business. The Company operates through three segments. The Non-clinical Test Consignment Agency Business segment conducts non-clinical is mainly engaged in the test on newly developed substances such as new drugs ,and tests the efficacy and pharmacodynamics of substances. In addition, this segment is engaged in the test of the safety of substances. The Bioinfra Business segment is engaged in animal laboratory design, construction, and maintenance. In addition, this segment provides equipment delivery. The Pet Medical Business segment is engaged in the development of veterinary medicine and the sale of companion animal products.
Calendar
2024-08-12
- Q2 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -17.48% | 160M | |
| -26.90% | 9.98B | |
| -16.78% | 2.75B | |
| -17.50% | 2.07B | |
| -24.25% | 1.59B | |
| +64.58% | 1.43B | |
| +31.92% | 824M | |
| -5.02% | 733M | |
| -29.59% | 508M | |
| +0.20% | 296M |
- Stock Market
- Equities
- A278650 Stock
